Intellia Therapeutics (NasdaqGM:NTLA) - Share price, News & Analysis

NTLA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

NTLA Stock Overview

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics.

Rewards

Revenue is forecast to grow 71.16% per year

Risk Analysis

Earnings are forecast to decline by an average of 1.3% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months

Shareholders have been diluted in the past year

Intellia Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Intellia Therapeutics
Historical stock prices
Current Share Price	US$47.74
52 Week High	US$202.73
52 Week Low	US$38.85
Beta	2.14
1 Month Change	-5.76%
3 Month Change	-44.82%
1 Year Change	-24.80%
3 Year Change	221.48%
5 Year Change	259.76%
Change since IPO	116.02%

Recent News & Updates

May 12

Intellia Therapeutics: Several Catalysts Expected For H2 2022

Intellia Therapeutics reported a loss of -$144M in Q1-2022. Further data on NTLA-2001 to be announced in the second half of June at the "EASL International Liver Congress" Preliminary results for NTLA-2002 expected for H2-2022. Liquidity is not at issue.

Shareholder Returns

	NTLA	US Biotechs	US Market
7D	-1.8%	1.4%	-2.7%
1Y	-24.8%	-21.7%	-12.9%

Return vs Industry: NTLA underperformed the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: NTLA underperformed the US Market which returned -12.9% over the past year.

Price Volatility

Is NTLA's price volatile compared to industry and market?
NTLA volatility
NTLA Average Weekly Movement	14.5%
Biotechs Industry Average Movement	12.4%
Market Average Movement	7.8%
10% most volatile stocks in US Market	16.9%
10% least volatile stocks in US Market	2.9%

Stable Share Price: NTLA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: NTLA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2014	485	John Leonard	https://www.intelliatx.com

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders.

Intellia Therapeutics Fundamentals Summary

How do Intellia Therapeutics's earnings and revenue compare to its market cap?
NTLA fundamental statistics
Market Cap	US$3.62b
Earnings (TTM)	-US$368.56m
Revenue (TTM)	US$37.86m

95.7x

P/S Ratio

-9.8x

P/E Ratio

Is NTLA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
NTLA income statement (TTM)
Revenue	US$37.86m
Cost of Revenue	US$313.63m
Gross Profit	-US$275.77m
Other Expenses	US$92.79m
Earnings	-US$368.56m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-4.86
Gross Margin	-728.38%
Net Profit Margin	-973.48%
Debt/Equity Ratio	0%

How did NTLA perform over the long term?

See historical performance and comparison

Valuation

Is Intellia Therapeutics undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

3.8x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NTLA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NTLA's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: NTLA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: NTLA is unprofitable, so we can't compare its PE Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NTLA's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: NTLA is overvalued based on its PB Ratio (3.8x) compared to the US Biotechs industry average (1.5x).

Future Growth

How is Intellia Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

-1.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NTLA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NTLA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NTLA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NTLA's revenue (71.2% per year) is forecast to grow faster than the US market (7.8% per year).

High Growth Revenue: NTLA's revenue (71.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if NTLA's Return on Equity is forecast to be high in 3 years time

Past Performance

How has Intellia Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-35.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: NTLA is currently unprofitable.

Growing Profit Margin: NTLA is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: NTLA is unprofitable, and losses have increased over the past 5 years at a rate of 35.8% per year.

Accelerating Growth: Unable to compare NTLA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NTLA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).

Return on Equity

High ROE: NTLA has a negative Return on Equity (-38.64%), as it is currently unprofitable.

Financial Health

How is Intellia Therapeutics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: NTLA's short term assets ($875.4M) exceed its short term liabilities ($126.1M).

Long Term Liabilities: NTLA's short term assets ($875.4M) exceed its long term liabilities ($122.9M).

Debt to Equity History and Analysis

Debt Level: NTLA is debt free.

Reducing Debt: NTLA has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NTLA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: NTLA has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 39.3% each year.

Dividend

What is Intellia Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate NTLA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NTLA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NTLA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NTLA's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NTLA has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure

CEO

John Leonard (64 yo)

4.33yrs

Tenure

US$9,773,560

Compensation

Dr. John M. Leonard, M.D., is an Executive Partner at Tyree & D'Angelo Partners. He has been a Director at IQVIA Holdings Inc. since February 2015 and has been its Lead Director since July 25, 2018. Dr. Le...

CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD9.77M) is above average for companies of similar size in the US market ($USD6.86M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: NTLA's management team is considered experienced (3.6 years average tenure).

Board Members

Experienced Board: NTLA's board of directors are considered experienced (7.1 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.3%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/22 00:00
End of Day Share Price	2022/05/20 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31